Anapolon is an oral steroid featuring 50 mg of the hormone Oxymetholone.
Many bodybuilders regard this substance as the most potent oral option available for significant mass increase. It's essential to understand that part of this mass gain will come from water retention linked to the steroid. Although Anapolon is a DHT-derived compound and does not convert to estrogen directly, it is still associated with numerous estrogen-related side effects. Some speculate that Anapolon may somehow stimulate the body’s natural estrogen receptors excessively. More robust anti-estrogens, like Letrozole and Exemestane, have been proven to greatly lower the body’s estrogen levels and can be very effective in minimizing these side effects when using Oxymetholone.
Anapolon acts quickly, and bodybuilders often begin to feel its effects by the end of the first week. Therefore, Oxymetholone is an excellent option to kickstart any bulking cycle. However, it’s crucial to recognize that Anapolon can be hepatotoxic if not used carefully. Bodybuilders are advised to limit cycles of this steroid to a maximum of 6 weeks and to keep daily doses below 100 mg.
While Oxymetholone can enhance appetite at appropriate doses, it may reduce hunger, leading to eating difficulties if taken in excessive amounts. Additionally, some users report experiencing headaches. Clearly, this is a potent substance that requires careful handling, but when used correctly, it can serve as a valuable asset in reaching fitness objectives.
Individuals intending to cycle with Oxymetholone typically use it in the first 3-6 weeks of a regimen that also includes an injectable form of Testosterone. To achieve even more significant mass gains, bodybuilders might opt to incorporate another injectable like Deca or Tren into their cycle. In such instances, the resulting mass and strength enhancements are likely to be quite substantial. Oxymetholone will suppress the body's natural testosterone production; hence, a post-cycle therapy (PCT) regimen is essential after discontinuation.